A multicenter,phase Ⅲ,randomized open-label clinical study of BL-B01D1 versus chemotherapy physician-selected in recurrent/ metastatic nasopharyngeal carcinoma patients treated with PD-1/L1 monoclonal (ChiCTR) - Oct 16, 2026 - P3 | N=368 | Completed | Sponsor: Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
New P3 trial • Head and Neck Cancer • Nasopharyngeal Carcinoma • Oncology • Solid Tumor • PD-L1
|